Mometasone furoate and fluticasone furoate are equally effective in restoring nasal epithelial barrier dysfunction in allergic rhinitis

• Main Authors: Maria Doulaptsi, Tine Wils, Peter W. Hellings, Katleen Martens, Ricard Farré, Maria Vicario, Wytske Fokkens, Emmanuel Prokopakis, Brecht Steelant
• Format: Article
• Language: English
• Published: Elsevier 2021-09-01
• Series: World Allergy Organization Journal
• Subjects: Fluticasone furoate; Mometasone furoate; Tight junctions; Epithelial integrity; Allergic rhinitis
• Online Access: http://www.sciencedirect.com/science/article/pii/S193945512100079X

Tight junction defects (TJ) have been associated with a defective epithelial barrier function in allergic rhinitis (AR). Intranasal corticosteroids are potent drugs frequently used to treat AR and are shown to restore epithelial integrity by acting on TJs and by reducing type 2 cytokine production. However, the effect of different classes of intranasal corticosteroids on the epithelial barrier has not been studied. Therefore, we compared the effect of 2 intranasal corticosteroids, ie, fluticasone furoate (FF) and mometasone furoate (MF) on epithelial barrier function. Both FF and MF similarly increased trans-epithelial electrical resistance of primary nasal epithelial cell cultures from AR patients. In a house dust mite-induced allergic asthma mouse model, FF and MF had similar beneficial effects on fluorescein isothiocyanate–dextran 4 kDa mucosal permeability, eosinophilic infiltration and IL-13 levels. Both molecules increased mRNA expression of the TJ proteins occludin and zonula occludens-1, thereby restoring epithelial barrier function. Lastly, we showed that long-term FF treatment also increased expression of occludin in AR patients compared to controls. In conclusion, both FF and MF effectively restore epithelial barrier function by increasing expression of TJ proteins in AR patients.